Skip to main content

ADVERTISEMENT

Maria Asimopoulos

Quiz
09/09/2021
Maria Asimopoulos
True or False: The active ingredient in an H2 blocker is esomeprazole/omeprazole.
True or False: The active ingredient in an H2 blocker is esomeprazole/omeprazole.
True or False: The active...
09/09/2021
Pharmacy Learning Network
Quiz
09/09/2021
Maria Asimopoulos
Which of the following foods most commonly triggers heartburn?
Which of the following foods most commonly triggers heartburn?
Which of the following foods...
09/09/2021
Pharmacy Learning Network
News
09/09/2021
Maria Asimopoulos
“Future research on the interaction between known [systemic lupus erythematosus]-specific modifiable risk factors and risk of stroke and [myocardial infarction] to support development of prevention and treatment strategies are needed,”...
“Future research on the interaction between known [systemic lupus erythematosus]-specific modifiable risk factors and risk of stroke and [myocardial infarction] to support development of prevention and treatment strategies are needed,”...
“Future research on the...
09/09/2021
First Report Managed Care
Quiz
09/09/2021
Maria Asimopoulos
True or False: The duration of acid control is longer with an H2 blocker and antacid vs an antacid alone.
True or False: The duration of acid control is longer with an H2 blocker and antacid vs an antacid alone.
True or False: The duration of...
09/09/2021
Pharmacy Learning Network
News
09/07/2021
Maria Asimopoulos
“Clinic pharmacists in multidisciplinary outpatient clinics are effective at identifying and resolving medication-related problems,” study authors wrote.
“Clinic pharmacists in multidisciplinary outpatient clinics are effective at identifying and resolving medication-related problems,” study authors wrote.
“Clinic pharmacists in...
09/07/2021
Pharmacy Learning Network
News
08/26/2021
Maria Asimopoulos
“To reduce their dissonance, the participants employed several strategies, including coercive measures,” study authors noted.
“To reduce their dissonance, the participants employed several strategies, including coercive measures,” study authors noted.
“To reduce their dissonance, the...
08/26/2021
Annals of Long-Term Care
Headshots of Ilene Warner-Maron, Alden Geriatrics, and Richard Stefanacci, Trinity Health PACE
Interview
08/20/2021
Maria Asimopoulos
Ilene Warner-Maron, PHD, RN-BC-CWCN, NHA, president, Alden Geriatric Consultants, Inc, and Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, senior physician, Trinity Health PACE, offer insight into potential benefits and consequences of the...
Ilene Warner-Maron, PHD, RN-BC-CWCN, NHA, president, Alden Geriatric Consultants, Inc, and Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, senior physician, Trinity Health PACE, offer insight into potential benefits and consequences of the...
Ilene Warner-Maron, PHD,...
08/20/2021
Annals of Long-Term Care
Headshot of Janet Freberger and Aileen Chou on a blue background underneath the PopHealth Perspectives logo.
Podcasts
08/17/2021
Julie Gould
Maria Asimopoulos
Janet Freberger, PT, PhD, professor, and Aileen Chou, PT, DPT, PhD student, Department of Physical Therapy at the University of Pittsburgh, discuss their research about patients undergoing rehabilitation for stroke in acute care hospitals,...
Janet Freberger, PT, PhD, professor, and Aileen Chou, PT, DPT, PhD student, Department of Physical Therapy at the University of Pittsburgh, discuss their research about patients undergoing rehabilitation for stroke in acute care hospitals,...
Janet Freberger, PT, PhD,...
08/17/2021
Annals of Long-Term Care
Headshot of Shephard Mpofu on a blue background underneath the PopHealth Perspectives logo.
Videos
08/16/2021
Julie Gould
Maria Asimopoulos
Shephard Mpofu, MD, senior vice president and chief medical officer, Novartis Gene Therapies, discusses findings from SPR1NT, a phase 3 clinical trial in which Zolgensma (onasemnogene abeparvovec-xioi) was effective in treating patients with...
Shephard Mpofu, MD, senior vice president and chief medical officer, Novartis Gene Therapies, discusses findings from SPR1NT, a phase 3 clinical trial in which Zolgensma (onasemnogene abeparvovec-xioi) was effective in treating patients with...
Shephard Mpofu, MD, senior vice...
08/16/2021
First Report Managed Care